BofA Securities downgraded Lyra Therapeutics from Buy to Underperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/7/2024 | $12.00 → $2.00 | Buy → Neutral | H.C. Wainwright |
| 5/7/2024 | $10.00 → $0.50 | Buy → Hold | Jefferies |
| 5/7/2024 | Buy → Underperform | BofA Securities | |
| 5/6/2024 | Outperform → Mkt Perform | William Blair | |
| 10/6/2023 | $15.00 | Buy | BTIG Research |
| 8/31/2023 | $12.00 | Buy | H.C. Wainwright |
| 5/24/2022 | $15.00 | Overweight | Cantor Fitzgerald |
SC 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
Accomplished financial executive with extensive strategic and operational leadership in emerging growth and commercial stage healthcare companies Extensive experience in private and public equity financings with more than $1 billion raised Incendia Therapeutics, a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve cancer outcomes, today announced the appointment of Bradford Smith as Chief Financial Officer (CFO). Smith is an accomplished financial executive with more than 30 years of strategic and operational leadership in emerging growth and commercial stage healthcare companies
Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension study indicating no product-related serious adverse events and general consistency with the primary treatment phase WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the third quarter ended September 30, 2024 and provided a corporate up
-- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the pivotal Phase 3 ENLIGHTEN 2 clinical trial of LYR-210 in adult patients with CRS who have not had prior ethmoid sinus surgery, is fully enrolled. LYR-210 is a bioresorbable nasal implant designed to deliver six months of continuous anti-inflammatory medication (mometasone furoate) to the sinonasal passages for the treatment of CRS. Topline results from ENLIGHTEN
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)
8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)
10-Q - Lyra Therapeutics, Inc. (0001327273) (Filer)
Accomplished financial executive with extensive strategic and operational leadership in emerging growth and commercial stage healthcare companies Extensive experience in private and public equity financings with more than $1 billion raised Incendia Therapeutics, a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve cancer outcomes, today announced the appointment of Bradford Smith as Chief Financial Officer (CFO). Smith is an accomplished financial executive with more than 30 years of strategic and operational leadership in emerging growth and commercial stage healthcare companies
H.C. Wainwright downgraded Lyra Therapeutics from Buy to Neutral and set a new price target of $2.00 from $12.00 previously
Jefferies downgraded Lyra Therapeutics from Buy to Hold and set a new price target of $0.50 from $10.00 previously
BofA Securities downgraded Lyra Therapeutics from Buy to Underperform